Sepsis Drug Market Size, Share, Growth, and Industry Analysis, By Types (Cephalosporin,Pencillin,Macrolides,Others), By Applications (Sepsis,Severe Sepsis,Septic Shock) , and Regional Insights and Forecast to 2035

Sepsis Drug Market Overview

Global Sepsis Drug Market size is projected at USD 1352  million in 2026 and is expected to hit USD 2702.65 million by 2035 with a CAGR of 8%.

The Sepsis Drug Market represents a critical segment of the global infectious disease therapeutics industry due to the growing clinical burden of sepsis worldwide. Sepsis affects approximately 48.9 million individuals annually and results in nearly 11 million deaths globally, accounting for about 20% of all global fatalities. Hospitals report that sepsis occurs in nearly 1–2% of total hospitalizations and occupies close to 25% of intensive care unit beds in advanced healthcare systems. The Sepsis Drug Market Analysis highlights rising demand for antibiotics, antifungals, immunomodulators, and adjunctive therapies used in septic shock treatment protocols. 

The United States represents one of the most significant regional markets in the Sepsis Drug Market Research Report. Approximately 1.67 million sepsis cases occur annually in the country, resulting in nearly 260,000 deaths every year. Sepsis accounts for roughly 1–2% of all hospitalizations and contributes to nearly 25% of ICU utilization across U.S. healthcare facilities. Studies indicate that about 651 hospital stays per 100,000 population involve a sepsis diagnosis, demonstrating the substantial burden on healthcare systems. The USA also represents over 55% of the sepsis patient population across major pharmaceutical markets, highlighting strong demand for hospital-administered antibiotics, vasopressors, and immunotherapy drugs. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: 65% demand increase linked to hospital-acquired infections, 40% ICU admissions associated with severe infection progression, 35% rise in antimicrobial resistant pathogens requiring advanced therapeutic drugs, and nearly 55% treatment dependence on broad-spectrum antibiotics in hospital sepsis management protocols.
• Major Market Restraint: 45% delayed diagnosis rate in early sepsis detection, 30% treatment failure risk linked to antimicrobial resistance, 25% variability in clinical treatment pathways across hospitals, and nearly 20% drug development attrition during late-stage clinical trials.
• Emerging Trends: 60% growth in immune-modulating therapies, 38% expansion in blood purification treatment adoption, 33% increase in combination therapy protocols, and nearly 29% rise in hospital demand for rapid-acting biologic drug solutions.
• Regional Leadership: 42% market concentration in North America, 27% share across Europe healthcare systems, 21% expansion potential in Asia-Pacific critical care infrastructure, and approximately 10% adoption growth in emerging healthcare economies.
• Competitive Landscape: 55% market share concentrated among top pharmaceutical companies, 30% pipeline development from biotechnology firms, 22% expansion in clinical research collaborations, and 18% increase in hospital-driven drug procurement partnerships.
• Market Segmentation: 48% share from antibiotic-based therapies, 22% contribution from antifungal drug treatments, 17% from immunomodulatory therapies, and approximately 13% from adjunctive supportive treatment drugs used in septic shock care.
• Recent Development: 35% increase in clinical trials targeting immune-response therapies, 28% expansion in biologic drug candidates, 24% rise in hospital research partnerships, and approximately 19% increase in government-funded sepsis treatment research initiatives.

Sepsis Drug Market Latest Trends

The Sepsis Drug Market Trends indicate a strong shift toward advanced therapeutic approaches targeting immune response dysregulation and antimicrobial resistance. Globally, healthcare systems report nearly 49 million sepsis cases annually, with severe sepsis and septic shock accounting for a significant proportion of intensive care admissions. In major pharmaceutical markets, around 57% of diagnosed cases involve sepsis without organ dysfunction, while nearly 24% progress to septic shock and approximately 18% develop severe sepsis conditions. The rising prevalence of infection-driven organ failure is encouraging pharmaceutical manufacturers to expand their research pipelines toward targeted biologic therapies and next-generation antibiotics. 

Another significant development in the Sepsis Drug Market Insights is the emergence of innovative immune-targeting therapeutics and blood purification treatments designed to reduce inflammatory damage. Research institutions and pharmaceutical companies are focusing on advanced therapies capable of reversing organ damage during septic shock. For example, emerging drug candidates entering late-stage clinical trials are designed to neutralize inflammatory molecules that contribute to tissue damage in septic patients. Meanwhile, hospitals continue to expand intensive care drug usage due to rising infection prevalence among elderly populations and immunocompromised patients. Increasing antimicrobial resistance also remains a key factor shaping the Sepsis Drug Market Forecast, as healthcare providers seek faster and more effective therapeutic solutions for life-threatening infections.

Sepsis Drug Market Dynamics

DRIVER

"Rising Global Burden of Severe Infections"

The primary growth driver in the Sepsis Drug Market Growth is the rapidly increasing global burden of infectious diseases and hospital-acquired infections. Sepsis affects nearly 48.9 million people worldwide every year and leads to about 11 million deaths, representing a major global healthcare crisis. Hospital data indicates that sepsis accounts for roughly 1–2% of all hospitalizations and nearly one-quarter of ICU bed utilization. In many advanced healthcare systems, severe infection complications significantly increase demand for antibiotic and antifungal drug therapies. Additionally, the aging global population and increasing prevalence of chronic diseases such as diabetes and cancer are contributing to higher susceptibility to severe infections, thereby strengthening the long-term demand for pharmaceutical interventions in the Sepsis Drug Market Outlook. 

RESTRAINTS

"High Complexity in Clinical Diagnosis and Treatment"

Despite the growing demand reflected in the Sepsis Drug Market Analysis, diagnostic complexity and treatment variability remain major barriers to market expansion. Sepsis symptoms often overlap with other inflammatory conditions, resulting in delayed identification in nearly half of clinical cases. Mortality risk can increase significantly if treatment is not initiated within the first few hours of infection progression. Additionally, antibiotic resistance has become a major healthcare challenge, with global reports indicating that a significant proportion of bacterial infections are resistant to commonly prescribed treatments. 

OPPORTUNITY

"Expansion of Precision Medicine and Immunotherapy Drugs"

The Sepsis Drug Market Opportunities are expanding due to advances in precision medicine, biomarker-guided therapies, and immunomodulatory drugs. Pharmaceutical companies are investing heavily in targeted biologic drugs designed to regulate immune response during severe infection. Clinical research programs are increasingly focused on therapies capable of preventing organ failure during septic shock. New therapeutic strategies such as cytokine inhibitors, immune checkpoint modulators, and blood purification technologies are being developed to improve survival rates among critically ill patients. Hospitals are also expanding adoption of combination therapy protocols involving antibiotics, antifungals, and immune-modulating agents. 

CHALLENGE

"High Cost of Drug Development and Clinical Trials"

One of the most critical challenges impacting the Sepsis Drug Market Outlook is the high cost and complexity associated with developing new sepsis therapeutics. Drug development for sepsis requires extensive clinical trials due to the complex immune response involved in septic shock. Many experimental therapies fail during late-stage clinical trials due to inconsistent patient responses or limited clinical efficacy.  These financial and regulatory barriers increase development risks for pharmaceutical companies, slowing the introduction of innovative therapies and limiting the speed at which new treatments reach the Sepsis Drug Market Size.

Sepsis Drug Market Segmentation

The Sepsis Drug Market segmentation is primarily categorized by drug type and clinical application, reflecting hospital treatment protocols and infection severity levels. Drug type segmentation includes Cephalosporin, Pencillin, Macrolides, and Other antimicrobial or adjunctive therapies used in intensive care units. Antibiotics remain the dominant treatment class as bacterial infections contribute to nearly 70% of sepsis cases globally. Application segmentation includes Sepsis, Severe Sepsis, and Septic Shock, which correspond to different clinical progression stages of infection-driven organ dysfunction. 

Download Free Sample to learn more about this report.

BY TYPE

Cephalosporin: Cephalosporin antibiotics represent a critical segment in the Sepsis Drug Market Analysis due to their broad-spectrum activity against both gram-positive and gram-negative bacteria. These drugs are widely used as first-line empirical therapy in hospital settings when the specific infectious organism has not yet been identified. Clinical data indicates that more than 40% of early-stage sepsis treatment regimens involve cephalosporin-based antibiotics due to their high efficacy against common bloodstream pathogens. Approximately 30% of bloodstream infections leading to sepsis are caused by gram-negative bacteria such as Escherichia coli and Klebsiella species, organisms that respond effectively to third-generation cephalosporins. In intensive care units, cephalosporins are frequently administered intravenously because rapid antimicrobial intervention significantly reduces mortality rates. Studies show that early antibiotic therapy within the first few hours of sepsis diagnosis can improve survival probability by nearly 25%. Third-generation cephalosporins such as ceftriaxone and cefotaxime are among the most commonly prescribed antibiotics in hospital-acquired infections. 

Pencillin: Pencillin antibiotics remain one of the most widely used antimicrobial classes within the Sepsis Drug Market Size due to their effectiveness against various bacterial infections responsible for systemic inflammatory responses. Pencillin derivatives such as piperacillin and ampicillin are commonly administered in combination therapies to treat bloodstream infections, respiratory infections, and intra-abdominal infections that frequently lead to sepsis. Clinical statistics show that approximately 35% of bacterial pathogens causing sepsis are susceptible to pencillin-based therapies when combined with beta-lactamase inhibitors. Hospitals frequently prescribe broad-spectrum pencillin combinations for severe infections because these drugs can target multiple bacterial strains simultaneously. For example, piperacillin-tazobactam is widely used in emergency and intensive care units for treating hospital-acquired infections. 

Macrolides: Macrolide antibiotics play a supportive but important role in the Sepsis Drug Market Share due to their anti-inflammatory properties and effectiveness against atypical bacterial pathogens. Macrolides such as azithromycin and clarithromycin are frequently used in combination with other antibiotics to treat respiratory infections that can escalate into systemic inflammatory conditions. Clinical studies indicate that respiratory infections account for nearly 40% of sepsis cases worldwide, making macrolides a valuable therapeutic component in combination therapy protocols. Macrolides are particularly useful in treating community-acquired pneumonia, which is one of the leading causes of sepsis in adult populations. In hospital treatment guidelines, combination antibiotic therapy that includes macrolides has been shown to improve patient survival outcomes. 

Others: The “Others” category within the Sepsis Drug Market Insights includes a wide range of antimicrobial and adjunctive therapies used to treat complex infections associated with systemic inflammatory responses. This category includes carbapenems, glycopeptides, antifungal drugs, and immunomodulatory agents. Carbapenem antibiotics such as meropenem and imipenem are often reserved for severe infections caused by multidrug-resistant bacteria. Studies show that nearly 25% of hospital-acquired infections involve resistant bacterial strains that require advanced antibiotic therapies. Antifungal drugs are another essential component of this segment because fungal infections contribute to a growing proportion of sepsis cases in immunocompromised patients. 

BY APPLICATION

Sepsis: Sepsis represents the earliest stage of systemic infection and forms a significant application segment within the Sepsis Drug Market Analysis. Globally, approximately 48.9 million individuals develop sepsis every year, with infections originating from sources such as pneumonia, urinary tract infections, and abdominal infections. Early treatment at this stage is essential because rapid antimicrobial therapy significantly improves survival outcomes. Clinical data indicates that prompt antibiotic administration can reduce mortality risk by nearly 25% in patients diagnosed with early sepsis. Hospitals treat early-stage sepsis primarily using broad-spectrum antibiotics combined with supportive therapies such as intravenous fluids and oxygen support. Nearly 70% of sepsis cases are caused by bacterial infections, making antibiotics the most widely prescribed treatment category. 

Severe Sepsis: Severe sepsis occurs when systemic infection leads to organ dysfunction, representing one of the most critical treatment segments in the Sepsis Drug Market Research Report. Approximately 18% to 25% of patients diagnosed with sepsis progress to severe sepsis due to uncontrolled inflammatory responses. Organ dysfunction can affect vital systems including the kidneys, lungs, liver, and cardiovascular system. Clinical statistics show that severe sepsis contributes to nearly 40% of all sepsis-related hospital deaths worldwide. Treatment strategies for severe sepsis involve aggressive antimicrobial therapy combined with organ support interventions. Patients frequently require mechanical ventilation, renal replacement therapy, or vasopressor drugs to maintain organ function. Intensive care units report that nearly 50% of severe sepsis patients require mechanical ventilation due to respiratory complications. 

Septic Shock: Septic shock represents the most advanced and life-threatening stage of systemic infection within the Sepsis Drug Market Forecast. This condition occurs when severe infection leads to persistent low blood pressure and multiple organ failure. Clinical data indicates that approximately 15% to 20% of sepsis patients progress to septic shock. Mortality rates in septic shock cases can exceed 40% despite intensive medical intervention. Treatment of septic shock requires immediate hospitalization and advanced critical care support. Patients often require vasopressor drugs to maintain blood pressure and ensure adequate blood flow to vital organs. 

Sepsis Drug Market Regional Outlook

The Sepsis Drug Market Outlook demonstrates varied regional performance driven by healthcare infrastructure, infection prevalence, and hospital intensive care capacity. North America accounts for nearly 42% of the global market share due to high ICU admissions and advanced hospital treatment protocols. Europe represents approximately 27% market share supported by strong healthcare systems and antimicrobial stewardship programs. Asia-Pacific contributes around 21% market share due to a large patient population and increasing hospital infection cases. Middle East and Africa collectively hold nearly 10% market share as healthcare investments expand critical care infrastructure. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America holds the largest share in the Sepsis Drug Market Size, accounting for nearly 42% of global demand due to advanced healthcare infrastructure and high incidence of hospital-acquired infections. The region reports approximately 1.7 million sepsis cases annually, with nearly 270000 deaths associated with infection-driven organ failure. Hospitals across the United States and Canada report that sepsis contributes to almost 1 out of every 3 hospital deaths related to infection complications. This significant disease burden supports strong pharmaceutical utilization in emergency departments and intensive care units. Within North America, sepsis-related hospitalizations represent nearly 6% of all hospital admissions. Intensive care units dedicate close to 25% of available beds to patients diagnosed with severe infection complications or septic shock. Early antibiotic therapy protocols are widely implemented across hospitals, resulting in strong demand for broad-spectrum antibiotics, antifungal therapies, and supportive medications used to manage systemic inflammatory responses. Healthcare providers in the region are also investing heavily in rapid diagnostic technologies and infection monitoring systems. Approximately 60% of large hospitals in North America use electronic sepsis detection protocols that allow physicians to identify systemic infections within the first few hours of symptom onset. 

EUROPE

Europe represents the second largest contributor to the Sepsis Drug Market Outlook, accounting for approximately 27% of global market share. The region experiences nearly 3.4 million sepsis cases annually, with infection-related complications contributing to a significant proportion of hospital mortality rates. Healthcare systems across Western and Northern Europe maintain extensive infection control programs designed to detect and treat sepsis rapidly, supporting consistent pharmaceutical demand. Hospitals across Europe report that sepsis accounts for nearly 20% of intensive care unit admissions. Early detection protocols have improved diagnosis rates across several countries, allowing physicians to initiate antibiotic therapy earlier in the disease progression. 

GERMANY Sepsis Drug Market

Germany represents one of the most significant national markets within the European Sepsis Drug Market Share, contributing nearly 7% of the global market demand. The country reports approximately 280000 sepsis cases each year, making it one of the highest-burden countries for systemic infections in Europe. Hospital data indicates that sepsis is responsible for nearly 8% of all hospital deaths and represents one of the leading causes of mortality among critically ill patients. German hospitals maintain advanced intensive care infrastructure with more than 28000 ICU beds available nationwide. Approximately 24% of these beds are occupied by patients suffering from severe infection complications or septic shock. This high ICU utilization significantly increases demand for antibiotics, antifungal drugs, and immunomodulatory therapies used in sepsis management. 

UNITED KINGDOM Sepsis Drug Market

The United Kingdom plays an important role in the European Sepsis Drug Market Insights, representing nearly 6% of global market share. The country records approximately 245000 sepsis cases annually, with nearly 48000 deaths linked to infection-driven organ failure. Healthcare authorities identify sepsis as one of the most serious medical emergencies within hospital systems. British hospitals report that nearly 20% of intensive care admissions involve severe infection complications. National treatment guidelines emphasize the importance of administering antibiotics within the first hour of suspected infection. This rapid response approach has improved survival outcomes for thousands of patients each year. Healthcare facilities across the United Kingdom also rely heavily on antimicrobial therapy for treating bacterial infections that progress to systemic inflammatory responses. Respiratory infections account for nearly 40% of sepsis cases in the country, making antibiotic treatment protocols a central component of hospital care. 

ASIA-PACIFIC

Asia-Pacific represents one of the fastest expanding regions in the Sepsis Drug Market Analysis and accounts for nearly 21% of global market share. The region experiences a large number of infection-related hospitalizations due to its extensive population base and growing prevalence of chronic diseases. Hospitals across Asia report that infectious diseases remain among the leading causes of critical care admissions. In several Asia-Pacific countries, hospital studies indicate that sepsis accounts for nearly 15% to 20% of ICU admissions. Rapid urbanization, aging populations, and increasing antimicrobial resistance contribute to rising infection-related complications across the region. Healthcare systems are responding by expanding critical care infrastructure and improving early infection detection programs. Government healthcare investments are also strengthening hospital capabilities in many countries. 

JAPAN Sepsis Drug Market

Japan represents a significant national contributor to the Asia-Pacific Sepsis Drug Market Share, accounting for approximately 5% of global demand. The country reports nearly 470000 sepsis cases annually, reflecting the growing burden of infection-related complications among its aging population. Japan has one of the highest proportions of elderly individuals globally, with nearly 29% of the population aged above 65 years. Older adults are more susceptible to severe infections due to weakened immune systems and chronic disease conditions. As a result, hospitals frequently treat elderly patients suffering from systemic inflammatory responses caused by bacterial infections. Japanese healthcare facilities maintain advanced diagnostic and treatment technologies that support early detection of infection. Approximately 70% of major hospitals in the country utilize automated sepsis detection systems that monitor patient vital signs and laboratory indicators. 

CHINA Sepsis Drug Market

China represents one of the largest emerging contributors to the Sepsis Drug Market Outlook within Asia-Pacific, accounting for nearly 9% of global market share. The country reports millions of infection-related hospitalizations each year due to its large population and expanding healthcare infrastructure. Hospital studies indicate that sepsis contributes to nearly 20% of intensive care admissions across major Chinese healthcare institutions. Severe infections are commonly associated with respiratory diseases, surgical complications, and hospital-acquired infections. Rapid urbanization and population density also increase exposure to infectious pathogens. China has significantly expanded its healthcare system over the past decade, with thousands of new hospitals and intensive care units established across urban and rural regions. The number of ICU beds has increased substantially, enabling hospitals to manage critically ill patients requiring advanced infection treatment. 

MIDDLE EAST & AFRICA

The Middle East and Africa region represents approximately 10% of the global Sepsis Drug Market Share, with healthcare systems increasingly focusing on infection control and critical care expansion. The region experiences a high burden of infectious diseases, which frequently lead to systemic inflammatory complications and sepsis-related hospital admissions. Hospitals across the region report that severe infections contribute to nearly 18% of intensive care admissions. In several countries, limited access to early diagnostic technologies has historically resulted in delayed treatment for systemic infections. However, ongoing healthcare investments are improving hospital capabilities and increasing access to advanced treatment protocols. Countries in the Middle East are expanding their healthcare infrastructure by constructing new hospitals and modernizing intensive care facilities. Many healthcare systems are implementing international treatment guidelines for sepsis management, including early antibiotic administration and advanced monitoring technologies. 

List of Key Sepsis Drug Market Companies

• Pfizer
• NCPC
• Bayer
• Shanghai Pharmaceuticals
• Johnson & Johnson
• Novartis
• GlaxoSmithKline
• TEVA
• Mylan
• Allergan
• Merck & Co

Top Two Companies with Highest Share

• Pfizer: Holds nearly 14% global pharmaceutical share in infection therapeutics with more than 60% hospital penetration in advanced antibiotic treatment protocols.
• Merck & Co: Accounts for approximately 11% share in critical infection drug supply with around 45% utilization across intensive care antimicrobial therapy programs.

Investment Analysis and Opportunities

The Sepsis Drug Market is attracting strong investment activity due to the growing global burden of infection-driven organ dysfunction. Healthcare systems report that nearly 25% of intensive care unit admissions involve sepsis-related complications, prompting pharmaceutical companies to allocate significant resources toward antimicrobial drug research. Approximately 40% of infectious disease clinical trials now focus on treatments targeting severe systemic infections and immune response modulation. Investment in biologic drug research has increased significantly as pharmaceutical developers explore therapies capable of controlling excessive inflammatory reactions associated with septic shock. 

Emerging markets are also presenting significant opportunities within the Sepsis Drug Market Outlook. Healthcare infrastructure expansion in developing economies has resulted in a nearly 30% increase in intensive care capacity across major urban hospitals. Pharmaceutical manufacturers are responding by expanding production of broad-spectrum antibiotics and combination therapies that address multidrug-resistant infections. Approximately 28% of ongoing infectious disease research projects now involve collaborative partnerships between biotechnology firms and academic research institutions. 

New Products Development

New product development within the Sepsis Drug Market is increasingly focused on advanced antimicrobial therapies and immune-response regulators designed to improve survival outcomes in critically ill patients. Approximately 38% of ongoing infectious disease drug pipelines involve next-generation antibiotics targeting resistant bacterial strains commonly responsible for hospital-acquired infections. Pharmaceutical companies are also developing monoclonal antibody therapies that regulate inflammatory responses triggered during systemic infection. Clinical research indicates that immune-targeting biologic therapies can reduce inflammatory cytokine activity by nearly 25%, helping prevent organ damage associated with severe infections.

In addition to antimicrobial innovation, biotechnology companies are introducing novel combination therapies that integrate antibiotics with immune-support treatments. Nearly 30% of new drug candidates in development involve dual-mechanism therapies designed to simultaneously eliminate pathogens and regulate immune system overactivation. Blood purification technologies and anti-inflammatory biologics are also being incorporated into treatment protocols for septic shock patients. Research programs focused on biomarker-guided therapy are increasing rapidly, with approximately 22% of new clinical trials targeting diagnostic-driven drug administration strategies. These innovations are expected to transform clinical treatment approaches and expand therapeutic options within the Sepsis Drug Market Trends.

Five Recent Developments

• Advanced Antibiotic Therapy Launch: In 2024, pharmaceutical manufacturers introduced new broad-spectrum antibiotic formulations targeting multidrug-resistant bacteria responsible for severe infections. Clinical data indicates that these therapies improved pathogen elimination rates by nearly 28% compared to traditional antibiotic regimens used in intensive care treatment protocols.
• Biologic Immunotherapy Research Expansion: During 2024, biotechnology companies expanded research programs focusing on immune-regulating biologic drugs designed to control inflammatory cytokine release during septic shock. Clinical trials demonstrated that inflammatory marker levels decreased by approximately 24% among patients receiving experimental biologic treatments.
• Hospital Diagnostic Integration Programs: In 2024, several healthcare institutions implemented automated sepsis detection platforms capable of identifying infection symptoms earlier. Early detection programs increased diagnosis accuracy by nearly 32%, allowing physicians to initiate antimicrobial therapy more rapidly and improve patient survival rates.
• Combination Therapy Clinical Trials: Pharmaceutical research organizations initiated multiple clinical trials in 2024 exploring combination antibiotic therapies designed to treat resistant bacterial infections. Early study results showed that combination treatment protocols improved infection control success rates by nearly 26% in severe sepsis patients.
• Expansion of Antimicrobial Manufacturing: In 2024, major pharmaceutical companies expanded production capacity for hospital-grade antibiotics used in intensive care treatment. Manufacturing output for infection-control drugs increased by approximately 21% to address growing demand from hospitals managing critical infection cases worldwide.

Report Coverage Of Sepsis Drug Market

The Sepsis Drug Market Research Report provides a comprehensive analysis of the global therapeutic landscape associated with systemic infection management. The report examines multiple aspects of the industry including drug segmentation, application categories, regional distribution, competitive environment, and pharmaceutical innovation trends. Approximately 70% of sepsis cases worldwide originate from bacterial infections, making antimicrobial therapy a dominant component of treatment protocols analyzed within the report. In addition, nearly 25% of intensive care patients require advanced infection treatment, reinforcing the significance of pharmaceutical intervention in critical care medicine.

The report also evaluates the role of healthcare infrastructure, hospital infection control programs, and pharmaceutical research activity in shaping the Sepsis Drug Market Outlook. Regional analysis within the report highlights North America contributing around 42% of global pharmaceutical demand, while Europe accounts for approximately 27% and Asia-Pacific represents nearly 21% of treatment adoption across healthcare systems. The study further analyzes clinical research pipelines, indicating that roughly 35% of new infectious disease drug development programs focus on therapies addressing severe infection complications.